Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Moderna, Inc. (MRNA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
103.29+3.02 (+3.01%)
At close: 04:00PM EDT
103.01 -0.28 (-0.27%)
After hours: 07:58PM EDT
Advertisement

Moderna, Inc.

200 Technology Square
Cambridge, MA 02139
United States
617 714 6500
https://www.modernatx.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees3,900

Key Executives

NameTitlePayExercisedYear Born
Mr. Stephane BancelCEO & Director4.97M392.58M1973
Dr. Stephen Hoge M.D.Pres2.41M56.52M1976
Mr. James M. MockChief Financial Officer1.49MN/A1977
Ms. Arpa GarayChief Commercial Officer2.67MN/A1979
Dr. Jerh Collins Ph.D.Chief Technical Operations & Quality OfficerN/AN/A1966
Dr. Melissa J. Moore Ph.D.Chief Scientific Officer & Member of Scientific Advisory BoardN/AN/AN/A
Mr. Brad MillerChief Information OfficerN/AN/A1973
Ms. Lavina Talukdar CFASr. VP & Head of Investor RelationsN/AN/AN/A
Ms. Shannon Thyme KlingerChief Legal Officer & Corp. Sec.N/AN/A1971
Colleen HusseySr. Director of Corp. CommunicationsN/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Moderna, Inc.’s ISS Governance QualityScore as of September 1, 2023 is 10. The pillar scores are Audit: 8; Board: 9; Shareholder Rights: 10; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement